Literature DB >> 19107777

Age of diagnosis influences serologic responses in children with Crohn's disease: a possible clue to etiology?

James Markowitz1, Subra Kugathasan, Marla Dubinsky, Ling Mei, Wallace Crandall, Neal LeLeiko, Maria Oliva-Hemker, Joel Rosh, Jonathan Evans, David Mack, Anthony Otley, Marian Pfefferkorn, Ron Bahar, Eric Vasiliauskas, Ghassan Wahbeh, Gary Silber, J Antonio Quiros, Iwona Wrobel, Justin Nebel, Carol Landers, Yoanna Picornell, Stephan Targan, Trudy Lerer, Jeffrey Hyams.   

Abstract

BACKGROUND: Crohn's disease (CD) is often associated with antibodies to microbial antigens. Differences in immune response may offer clues to the pathogenesis of the disease. The aim was to examine the influence of age at diagnosis on the serologic response in children with CD.
METHODS: Data were drawn from 3 North American multicenter pediatric inflammatory bowel disease (IBD) research consortia. At or shortly after diagnosis, pANCA, ASCA IgA, ASCA IgG, anti-ompC, and anti-CBir1 were assayed. The results were compared as a function of age at CD diagnosis (0-7 years versus 8-15 years).
RESULTS: In all, 705 children (79 <8 years of age at diagnosis, 626 >or=8 years) were studied. Small bowel CD was less frequent in the younger group (48.7% versus 72.6%; P < 0.0001), while colonic involvement was comparable (91.0% versus 86.5%). ASCA IgA and IgG were seen in <20% of those 0-7 years old compared to nearly 40% of those 8-15 years old (P < 0.001), while anti-CBir1 was more frequent in the younger children (66% versus 54%, P < 0.05). Anti-CBir1 detected a significant number of children in both age groups who otherwise were serologically negative. Both age at diagnosis and site of CD involvement were independently associated with expression of ASCA and anti-CBir1.
CONCLUSIONS: Compared to children 8-15 years of age at diagnosis, those 0-7 years are more likely to express anti-CBir1 but only half as likely to express ASCA. These age-associated differences in antimicrobial seropositivity suggest that there may be different, and as yet unrecognized, genetic, immunologic, and/or microbial factors leading to CD in the youngest children.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19107777      PMCID: PMC2726983          DOI: 10.1002/ibd.20831

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  25 in total

1.  Evaluation of serologic disease markers in a population-based cohort of patients with ulcerative colitis and Crohn's disease.

Authors:  W J Sandborn; E V Loftus; J F Colombel; K A Fleming; F Seibold; H A Homburger; B Sendid; R W Chapman; W J Tremaine; D K Kaul; J Wallace; W S Harmsen; A R Zinsmeister; S R Targan
Journal:  Inflamm Bowel Dis       Date:  2001-08       Impact factor: 5.325

2.  Prospective evaluation of neutrophil autoantibodies in 500 consecutive patients with inflammatory bowel disease.

Authors:  H Freeman; B Roeck; D Devine; C Carter
Journal:  Can J Gastroenterol       Date:  1997-04       Impact factor: 3.522

3.  Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup.

Authors:  E A Vasiliauskas; S E Plevy; C J Landers; S W Binder; D M Ferguson; H Yang; J I Rotter; A Vidrich; S R Targan
Journal:  Gastroenterology       Date:  1996-06       Impact factor: 22.682

4.  Antineutrophil cytoplasmic antibodies, anti-Saccharomyces cerevisiae antibodies, and specific IgE to food allergens in children with inflammatory bowel diseases.

Authors:  J Bartůnková; I Kolárová; A Sedivá; E Hölzelová
Journal:  Clin Immunol       Date:  2002-02       Impact factor: 3.969

5.  Role of serology and routine laboratory tests in childhood inflammatory bowel disease.

Authors:  Khalid Khan; Sarah Jane Schwarzenberg; Harvey Sharp; Deborah Greenwood; Sally Weisdorf-Schindele
Journal:  Inflamm Bowel Dis       Date:  2002-09       Impact factor: 5.325

6.  Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with Crohn's disease and ulcerative colitis: diagnostic value and correlation with disease phenotype.

Authors:  Anna Zholudev; David Zurakowski; Wes Young; Alan Leichtner; Athos Bousvaros
Journal:  Am J Gastroenterol       Date:  2004-11       Impact factor: 10.864

7.  Sero-reactivity to microbial components in Crohn's disease is associated with disease severity and progression, but not NOD2/CARD15 genotype.

Authors:  Ian D R Arnott; Carol J Landers; Elaine J Nimmo; Hazel E Drummond; Ben K R Smith; Stephan R Targan; Jack Satsangi
Journal:  Am J Gastroenterol       Date:  2004-12       Impact factor: 10.864

8.  Bacterial flagellin is a dominant antigen in Crohn disease.

Authors:  Michael J Lodes; Yingzi Cong; Charles O Elson; Raodoh Mohamath; Carol J Landers; Stephan R Targan; Madeline Fort; Robert M Hershberg
Journal:  J Clin Invest       Date:  2004-05       Impact factor: 14.808

9.  Diagnostic role and clinical correlates of anti-Saccharomyces cerevisiae antibodies (ASCA) and anti-neutrophil cytoplasmic antibodies (p-ANCA) in Italian patients with inflammatory bowel diseases.

Authors:  S Saibeni; C Folli; R de Franchis; G Borsi; M Vecchi
Journal:  Dig Liver Dis       Date:  2003-12       Impact factor: 4.088

10.  Comparison of serological markers of inflammatory bowel disease with clinical diagnosis in children.

Authors:  Sandeep K Gupta; Joseph F Fitzgerald; Joseph M Croffie; Marian D Pfefferkorn; Jean Pappas Molleston; Mark R Corkins
Journal:  Inflamm Bowel Dis       Date:  2004-05       Impact factor: 5.325

View more
  27 in total

1.  Serum antibodies and anthropometric data at diagnosis in pediatric Crohn's disease.

Authors:  Anna K Trauernicht; Steven J Steiner
Journal:  Dig Dis Sci       Date:  2011-11-11       Impact factor: 3.199

2.  Effects of age at disease onset and at treatment on serology in inflammatory bowel diseases.

Authors:  Gianluca Pellino
Journal:  Dig Dis Sci       Date:  2014-11-04       Impact factor: 3.199

Review 3.  How does knowledge from translational research impact our clinical care of pediatric inflammatory bowel disease patients?

Authors:  Lee A Denson
Journal:  Curr Gastroenterol Rep       Date:  2012-06

4.  Alterations in diversity of the oral microbiome in pediatric inflammatory bowel disease.

Authors:  Michael J Docktor; Bruce J Paster; Shelly Abramowicz; Jay Ingram; Yaoyu E Wang; Mick Correll; Hongyu Jiang; Sean L Cotton; Alexis S Kokaras; Athos Bousvaros
Journal:  Inflamm Bowel Dis       Date:  2011-10-10       Impact factor: 5.325

5.  A SPECIAL MEETING REVIEW EDITION: Clinical Research Highlights in IBD: Diagnosis and Anti-Tumor Necrosis Factor Monitoring: Digestive Disease Week 2013May 18-21, 2013 • Orlando, FloridaSpecial Reporting on:• Serological and Inflammatory IBD Marker Prevalence As Function of Age in a Large Cohort of Patients Presenting IBD-Like Gastrointestinal Symptoms• Prevalence of Antibodies to Adalimumab (ATA) and Correlation Between ATA and Low Serum Drug Concentration on CRP and Clinical Symptoms in a Prospective Sample of IBD Patients• Serum Adalimumab Levels and Antibodies Correlate with Endoscopic Intestinal Inflammation and Inflammatory Markers in Patients with Inflammatory Bowel Disease• Comparison of Early Measurement of Infliximab and Antibodies-to-Infliximab Serum Levels with Standard Trough Analysis• Trough Levels and Antidrug Antibodies Predict Safety and Success of Restarting Infliximab After a Long Drug Holiday• A Multi-Center Observational Study in Community Gastroenterology Practices Evaluating the Clinical Usage of Testing for Serum Levels of Infliximab and Antibodies to Infliximab• Preoperative Serum Biologic Levels Do Not Impact Postoperative Outcomes in Ulcerative Colitis• Higher Preoperative Serum Biologic Levels Are Associated with Postoperative Complications in Crohn's Disease PatientsWith Expert Commentary by: William J. Sandborn, MDProfessor and Chief, Division of GastroenterologyDirector, UCSD IBD CenterUC San Diego Health SystemLa Jolla, California.

Authors: 
Journal:  Gastroenterol Hepatol (N Y)       Date:  2013-08

6.  Familial Association of Granulocyte-Macrophage Colony-Stimulating Factor Autoantibodies in Inflammatory Bowel Disease.

Authors:  Sandra S Wright; Anna Trauernicht; Erin Bonkowski; Courtney A McCall; Elizabeth A Maier; Ramona Bezold; Kathleen Lake; Claudia Chalk; Bruce C Trapnell; Mi-Ok Kim; Subra Kugathasan; Lee A Denson
Journal:  J Pediatr Gastroenterol Nutr       Date:  2018-05       Impact factor: 2.839

Review 7.  New serological markers in pediatric patients with inflammatory bowel disease.

Authors:  Márta Kovács; Katalin Eszter Müller; Mária Papp; Péter László Lakatos; Mihály Csöndes; Gábor Veres
Journal:  World J Gastroenterol       Date:  2014-05-07       Impact factor: 5.742

Review 8.  Diagnostic advances in inflammatory bowel disease (imaging and laboratory).

Authors:  Maria E Moscandrew; Edward V Loftus
Journal:  Curr Gastroenterol Rep       Date:  2009-12

9.  Serological markers for inflammatory bowel disease in AIDS patients with evidence of microbial translocation.

Authors:  Anupa Kamat; Petronela Ancuta; Richard S Blumberg; Dana Gabuzda
Journal:  PLoS One       Date:  2010-11-15       Impact factor: 3.240

Review 10.  The role of the innate and adaptive immune system in pediatric inflammatory bowel disease.

Authors:  Lee A Denson
Journal:  Inflamm Bowel Dis       Date:  2013-08       Impact factor: 5.325

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.